Source:http://linkedlifedata.com/resource/pubmed/id/18993148
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10
|
pubmed:dateCreated |
2008-11-10
|
pubmed:abstractText |
On the basis of biologic studies of platelet reactivity, the recent American College of Cardiology and American Heart Association guidelines recommend a 600-mg loading dose (LD) of clopidogrel in patients who undergo percutaneous coronary intervention (PCI). There is, however, a lack of studies addressing the clinical impact of such a clopidogrel LD. The aim of this study was to compare the clinical efficacy and safety of a 600-mg LD of clopidogrel with that of a 300-mg LD in an unselected cohort of patients who underwent PCI. A cohort of 4,105 unselected patients who underwent PCI were included in the study and divided according to the LD used: the high-LD group (600 mg) included 3,146 patients, and the low-LD group (300 mg) included 959. The primary end point was the rate of major adverse cardiovascular events (MACEs) at 1 month. Patients in the low-LD group more often had diabetes mellitus and histories of myocardial infarction (36.8% vs 31.9%, p = 0.01). Left ventricular ejection fractions were similar (0.49 +/- 0.14 vs 0.48 +/- 0.14, p = 0.25). Angiographic and procedural characteristics were identical between the 2 groups. Patients in the high-LD group had fewer MACEs after 1 month (2.9% vs 5.2%, p <0.001). In multivariate analysis, an LD of 600 mg was significantly associated with MACEs at 1-month follow-up, with an odds ratio of 0.62 (95% confidence interval 0.41 to 0.95, p = 0.03). In conclusion, a 600-mg LD was associated with a significant decrease in the rate of post-PCI MACEs at 1 month, without any in-hospital increase in bleeding complications. The results of this study therefore support the current guidelines of a 600-mg LD of clopidogrel in patients who undergo PCI.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1879-1913
|
pubmed:author |
pubmed-author:BonelloLaurentL,
pubmed-author:De LabriolleAxelA,
pubmed-author:KentKenneth MKM,
pubmed-author:LemesleGillesG,
pubmed-author:LindsayJosephJ,
pubmed-author:PichardAugusto DAD,
pubmed-author:Pinto SlottowTina LTL,
pubmed-author:RoyProbalP,
pubmed-author:SatlerLowell FLF,
pubmed-author:SteinbergDaniel HDH,
pubmed-author:SuddathWilliam OWO,
pubmed-author:TorgusonRebeccaR,
pubmed-author:WaksmanRonR,
pubmed-author:XueZhenyiZ
|
pubmed:issnType |
Electronic
|
pubmed:day |
15
|
pubmed:volume |
102
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1318-22
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:18993148-Aged,
pubmed-meshheading:18993148-Angioplasty, Balloon, Coronary,
pubmed-meshheading:18993148-Cardiovascular Diseases,
pubmed-meshheading:18993148-Female,
pubmed-meshheading:18993148-Humans,
pubmed-meshheading:18993148-Male,
pubmed-meshheading:18993148-Middle Aged,
pubmed-meshheading:18993148-Platelet Aggregation Inhibitors,
pubmed-meshheading:18993148-Retrospective Studies,
pubmed-meshheading:18993148-Ticlopidine,
pubmed-meshheading:18993148-Time Factors
|
pubmed:year |
2008
|
pubmed:articleTitle |
Impact of a 600-mg loading dose of clopidogrel on 30-day outcome in unselected patients undergoing percutaneous coronary intervention.
|
pubmed:affiliation |
Department of Internal Medicine, Division of Cardiology, Washington Hospital Center, Washington, DC, USA.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|